Biography

Ian Ratcliffe has served as a member of our board of directors since February 2024. He is an executive managing partner of the Sands Capital Life Sciences Pulse strategy and an executive managing director of Sands Capital. Before joining Sands Capital, Ian was the chairman and chief executive officer of Enzymatics (now Qiagen), founder and chief executive officer of Stemgent (now Reprocell), and president of Upstate (now MilliporeSigma). Earlier in his career, he founded and led a number of privately held life science businesses spanning cell signaling, drug screening, genomics, sequencing, and cell culture. Ian holds a degree in Chemical Engineering from the University of Surrey and an M.B.A. from the Darden School at the University of Virginia.